FDA Suspends In-Person Requirement for Mifepristone Abortions: Decision Puts Women at Risk


WASHINGTON — In a letter dated April 12th, acting commissioner of the Food and Drug Administration, Janet Woodcock, M.D., announced that the FDA would not enforce in-person dispensing requirements for the abortion drug mifepristone during the remainder of the pandemic. Convincing the FDA to discard necessary safety precautions is part of the abortion industry’s long-term campaign […]

Leave a comment

Your email address will not be published. Required fields are marked *